Milford, Mass.-based Reprieve Cardiovascular said that it is developing devices intended for patients suffering from acute decompensated heart failure. The technology is part of the company’s Guided Diuretic Therapy, which is being investigated as a treatment for patients who are fluid-overloaded due to heart failure and is intended to speed up decongestion while protecting core organ function, shortening hospital stays and reducing re-hospitalizations.
Reprieve Cardio said that results from a feasibility study of its Guided Diuretic Therapy showed the system was able to alleviate symptoms and optimize fluid management in ADHF patients
“I have been impressed with the early experience in the EU, led by Prof. Ponikowski in Wroclaw, Poland, for treating patients with acutely decompensated heart failure with the Reprieve Cardiovascular technology. Effective decongestion is critical to the ability to eventually reduce hospital length-of-stay and readmissions. The proposed mechanism of action of Reprieve Cardiovascular’s Guided Diuretic Therapy is based on important physiological principles and can potentially address the problem of fluid overload in many heart failure patients. I am eager to offer this therapy to my patients once the appropriate clinical trials have confirmed its safety and effectiveness,” cardiologist Dr. Maria Costanzo of Downers Grove, Ill.-based Advocate Good Samaritan Hospital said in a prepared statement.
“We are thrilled with the initial results from the study that demonstrate a promising step towards a new therapy for patients facing heart failure. Reprieve Cardiovascular’s fluid management technology may precisely enable the controlled decongestive therapy that ADHF patients need. Our Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss when receiving diuretics. At Heart Failure 2018, we experienced overwhelming interest in our Late Breaking Clinical Trial presentation and Satellite Symposium, as well as numerous mentions in Acute Heart Failure presentations. We look forward to a similar response to our demonstration at the HFSA Scientific Meeting in September,” Reprieve Cardiovascular CEO Jim Dillon said in a press release.
In May, RenalGuard Solutions released results from a feasibility study of its RenalGuard-guided diuretic therapy intended to improve fluid management in patients with acute decompensated heart failure and alleviate related symptoms.